MAPT and frontotemporal dementia: One of its advantages is the ability to facilitate the modelling of human cell-type diseases, like Mari Nakamura et al. [100], who generated iPSC from patients and used CRISPR/Cas9 to insert MAPT genes to form frontotemporal family dementia (FTD) model and found that mutant tau proteins exhibited abnormalities such as reduced levels of phosphorylation.